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Background: This study investigated the local effect and acute toxicity of irinotecan and capecitabine with
concurrent intensity-modulated radiation therapy (IMRT) for the treatment of recurrent rectal cancer without prior
pelvic irradiation.
Methods: Seventy-one patients diagnosed with recurrent rectal cancer who did not previously receive pelvic
irradiation were treated in our hospital from October 2009 to July 2012. Radiotherapy was delivered to the pelvis,
and IMRT of 45 Gy (1.8 Gy per fraction), followed by a boost of 10 Gy to 16 Gy (2 Gy per fraction), was delivered to
the recurrent sites. The concurrent chemotherapy regimen was 50 mg/m2 irinotecan weekly and 625 mg/m2
capecitabine twice daily (Mon-Fri). Radical surgery was recommended for medically fit patients without extra-pelvic
metastases. The patients were followed up every 3 months. Tumor response was evaluated using CT/MRIs according
to the RECIST criteria or postoperative pathological findings. NCI-CTC 3.0 was used to score the toxicities.
Results: Forty-eight patients (67.6%) had confirmed recurrent rectal cancer without extra pelvic metastases, and
23 patients (32.4%) had extra pelvic metastases. Fourteen patients (19.7%) underwent radical resections (R0)
post-chemoradiation. A pathologic complete response was observed in 7 of 14 patients. A clinical complete
response was observed in 4 patients (5.6%), and a partial response was observed in 22 patients (31.0%). Only 5
patients (7.0%) showed progressive disease during or shortly after treatment. Of 53 symptomatic patients, clinical
complete and partial symptom relief with chemoradiation was achieved in 56.6% and 32.1% of patients, respectively.
Only 2 patients (2.8%) experienced grade 4 leukopenia. The most common grade 3 toxicity was diarrhea (16
[22.5%] patients). The median follow-up was 31 months. The cumulative local progression-free survival rate was
74.2% and 33.9% at 1 and 3 years after chemoradiation, respectively. The cumulative total survival rate was 80.1%
and 36.5% at 1 and 3 years after chemoradiation, respectively.
Conclusions: This study revealed that concurrent irinotecan and capecitabine with IMRT significantly relieves local
symptoms and exhibits promising efficacy with manageable toxicities in recurrent rectal cancer without prior
pelvic irradiation. Improving the rate of R0 resections will be investigated in a future study.
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Recent advances in pretreatment radiologic evaluation,
radiation and chemotherapy, and surgical techniques,
such as total mesorectal excision (TME), have led to a de-
clining incidence of locoregional recurrences for patients
with primary rectal cancer [1,2]. Nevertheless, some pa-
tients still develop pelvic recurrence with or without extra
pelvic metastases, especially in cases that did not receive
standard initial treatment. Generally, pelvic recurrences
portend a poor prognosis and are morbid, leading to
troublesome symptoms, including pelvic pain, bleeding,
and bowel obstruction [3,4].
Currently, there is no consensus for the treatment of
recurrent rectal cancer. Although radical surgery remains
the only therapy with curative potential, only approxi-
mately 20-30% of patients with recurrent rectal cancer can
undergo R0 resection [5]. Most patients cannot undergo
curative surgery due to locally unresectable disease, med-
ical unfitness, an unwillingness to accept the considerable
associated morbidity and mortality or additional unresect-
able pelvic metastases. There is no survival benefit of an
R2 resection compared with no resection [6].
Several studies have shown that radiotherapy (RT) is
an effective method of treatment for recurrent rectal
cancer, and a positive relationship between radiation
dose and clinical outcome in recurrent rectal cancer
has also been observed [7,8]. Therefore, there is a need
to adopt new techniques, such as intensity-modified
radiotherapy (IMRT), stereotactic body RT, or proton
and heavy ion RT, to safely deliver higher doses of radi-
ation and improve local control. The combination of
RT and chemotherapy with curative intent or a (neo)
adjuvant setting improves the clinical outcome of pa-
tients with recurrent rectal cancer [9]. However, the
optimal regimens for concurrent chemoradiation have
not been clearly defined. Radiation sensitization with
capecitabine has been shown to be effective for the
treatment of rectal cancer. FOLFOX is currently the
standard adjuvant chemotherapy; thus, most recurrent
patients have previously received oxaliplatin. Both pre-
clinical and clinical studies have revealed a synergistic
effect of CPT-11 or irinotecan when combined with
radiation and remarkable radiosensitizing activity of
CPT-11 [10]. Several small studies have evaluated CPT-
11 and capecitabine combined with radiation and dem-
onstrated that this treatment is well tolerated and
effective for primary rectal cancer [11-15]. However, no
previous prospective study has evaluated the efficacy
and safety of irinotecan and capecitabine concurrent
with IMRT for treatment of recurrent rectal cancer. Based
on these considerations, we carried out a phase II trial to
investigate the local effect and acute toxicity of irinotecan
and capecitabine concurrent with IMRT for the treatment
of recurrent rectal cancer.Materials and methods
Patients
Seventy-one patients with recurrent rectal cancer were
enrolled between October 2009 and November 2011. This
prospective study was approved by our institutional review
board (Fudan University Shanghai Cancer Center), and all
patients provided informed consent.
Eligibility criteria included patients with histologically
confirmed primary rectal adenocarcinoma; age between
18 and 75 years; Eastern Cooperative Oncology Group
(ECOG) performance score ≤2; adequate hematological,
liver function, and other laboratory parameters (leuco-
cytes >4.0 × 109/L, platelets >100 × 109/L, bilirubin <1.5
the upper limit of normal range (ULN); aspartate ami-
notransferase/alanine aminotransferase ≤2.5 × ULN; and
serum creatinine <1.25 × ULN).
All patients were discussed among our multidisciplin-
ary team (MDT) before treatment and diagnosed with a
pelvic recurrence either by histological confirmation or
typical appearance on PET/CT, computed tomography
(CT) or MRI imaging. Measurable lesions were observed
in the field of RT.
Exclusion criteria were as follows: prior pelvic irradi-
ation; prior chemotherapy with irinotecan in the last six
months; any other malignancy; significant coronary or car-
diac conditions; serious uncontrolled infection(s); a psy-
chiatric disorder; and pregnancy or lack of contraception
use in women with child-bearing potential.
Pretreatment evaluation
The pretreatment workup was conducted within two
weeks of the treatment start date and included complete
history and physical examination, digital rectal examin-
ation, colonoscopy (if possible), tumor biopsy (if pos-
sible), chest CT, abdominal CT and pelvic PET/CT or
CT or MRI, and complete laboratory tests.
Radiotherapy
RT was delivered with a linear accelerator using 6-MV
photons. Every patient had a planning CT scan in the
treatment position. IMRT planning was used for all
patients based on the planning CT imaging. The target
definition followed the recommendations of ICRU Re-
port No. 83 [16]. The target volumes and nearby organs
at risk were delineated on the Pinnacle 8.0 m planning
system. The gross tumor volume (GTV) was determined
by a combination of the findings on physical exam, CT,
MRI, and/or PET-CT. The clinical target volume (CTV)
included the GTV, internal iliac, pre-sacral and peri-rectal
nodal regions, external iliac nodal region (if recurrent le-
sions extended into gynecologic/genitourinary structures
or positive external iliac lymph nodes) and inguinal nodal
region (if recurrent lesions extended to the anal verge,
peri-anal skin or positive inguinal nodes). CTV was
Table 1 Patient characteristics (n = 71)
Characteristics No. %










Recurrence location (n = 101)
Peri-rectal region 34 33.7
Pre-sacral region 26 25.7
Internal iliac nodal region 23 22.8
Perineum 8 7.9
External iliac nodal region 6 5.9
Inguinal nodal region 4 4.0
Cai et al. Radiation Oncology  (2015) 10:57 Page 3 of 6generated according to the RTOG anorectal contouring
atlas, when available [17]. The PTV1 was generated with
a 0.5-1 cm asymmetrical margin around the CTV. A
5 mm expansion was used in areas where the CTV was
close to the small bowel, bladder and femoral heads,
and a 10 mm margin was used elsewhere. The PTV2
was generated by symmetrically expanding the GTV by
2 cm. The small bowel, bladder and femoral heads were
defined as organs at risk. Inverse planning with five to
seven equally spaced, coplanar IMRT fields were con-
structed. RT was delivered at a dose of 55–61 Gy in 30–
33 treatment fractions, 45 Gy in 25 fractions to PTV1
and 10–16 Gy in 5–8 fractions to PTV2.
Chemotherapy
Irinotecan and capecitabine were delivered concur-
rently with RT. Starting at day 1 of RT for the duration
of the irradiation (Mon-Fri), patients received capecita-
bine 625 mg/m2 orally within 30 minutes of finishing a
meal, as well as weekly irinotecan at 50 mg/m2 for five
consecutive weeks (days 1, 8, 15, 22, and 29).
Maintenance chemotherapy and surgery
After concurrent chemoradiotherapy, maintenance chemo-
therapy was recommended for all patients but was not
included in the study protocol. Maintenance chemo-
therapy for the patients was individualized, with no spe-
cific recommendations.
After concurrent chemoradiotherapy, the MDT, which
included a group of experienced colorectal surgeons, eval-
uated the clinical response of the tumor based on imaging
and examined the patient to determine whether they were
suitable resection candidates.
Follow-up
All patients with recurrent rectal cancer were evaluated
for local responses 3 months after concurrent chemoradi-
ation using CT, MRI, PET/CT or pathologic examination.
The patients continued in serial follow up every 3 months
with clinical examinations, abdominal and pelvic CTs or
MRIs. Tumor response was evaluated using CT/MRIs
according to the RECIST criteria or postoperative patho-
logical findings. Adverse events were assessed at least
weekly during RT using the National Cancer Institute
(NCI) common toxicity criteria (NCI-CTC version 3.0).
Statistical considerations
The primary efficacy endpoint for this study was local
response rate (complete or partial response). Secondary
efficacy endpoints included relief of local symptoms, acute
toxicity and survival.
The duration of local response and survival were ana-
lyzed using SPSS 17.0 statistical software. Survival wasanalyzed using the Kaplan-Meier method, and compari-
sons were made using log-rank tests.Results
Patient characteristics
A total of 71 patients with recurrent rectal cancer with a
median age of 53 years (range, 30–75 years) were enrolled.
Enrolled patients were predominantly male (47 men and
24 women). Isolated pelvic locoregional recurrences oc-
curred in 48 patients (67.6%), whereas 23 patients (32.4%)
developed extra pelvic metastases. A total of 101 recurrent
sites in all patients were included, 48 cases (67.6%) with
single sites of recurrence and 23 cases (32.4%) with mul-
tiple recurrences. Thirty-four recurrences (33.7%) were
located in the peri-rectal region, 26 (25.7%) in the pre-
sacral region, 6 (5.9%) at the external iliac nodal region
and 4 (4.0%) at the inguinal nodal region. After concurrent
chemoradiation, 56 patients (78.9%) received 5-FU-based
maintenance chemotherapy. The patient characteristics
are summarized in Table 1.
At primary diagnosis, the initial staging was as follows:
6 (8.5%) stage I patients, 13 (18.3%) stage II patients, and
52 (73.2%) stage III patients. A total of 45 patients (63.3%)
previously underwent low anterior resection, 25 (35.2%)
previously underwent abdominoperineal resection, and 1
(1.4%) previously underwent local excision. In addition,
61 patients (85.9%) previously received postoperative
chemotherapy consisting of 12 cycles (range, 2–12) of
5-FU plus oxaliplatin or 6 cycles (range, 6–8) capecita-
bine plus oxaliplatin.










Leukocytopenia 9 (12.7) 6 (8.5) 4 (5.6) 2 (2.8)
Thrombocytopenia 1 (1.4) 0 0 0
Non-hematological
Diarrhea 21 (29.6) 14 (19.7) 16 (22.5) 0
Cystitis 12 (16.9) 9 (12.7) 3 (4.2) 0
Dermatitis 8 (8.5) 13 (18.3) 7 (9.9) 0
Vomiting 4 (5.6) 3 (4.2) 0 0
Hand-foot syndrome 4 (5.6) 2 (2.8) 0 0
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The overall local response rate was 46.5% at 3 months
after concurrent chemoradiation. Complete response was
observed in 11 patients (15.5%). Fourteen patients (19.7%)
underwent radical resections (R0) post-chemoradiation. A
pathologic complete response (pCR) was observed in 7 of
14 patients. Complete clinical response was observed in 4
patients (5.6%), and a partial response was observed in 22
patients (31.0%). Stable disease was observed in 33 pa-
tients (46.5%). Progressive disease was observed in 5 pa-
tients (7%) during or shortly after treatment. Overall, local
control was achieved in 93% of patients at 3 months after
concurrent chemoradiation (Table 2).
Of 53 symptomatic patients, clinical complete and par-
tial symptom relief with chemoradiation was achieved in
56.6% and 32.1% of patients, respectively (Table 2).
Acute toxicity and dose intensity
Table 3 demonstrates the incidence of acute toxicity during
concurrent chemoradiation. Only 2 patients experienced
grade 4 leukopenia. Diarrhea was the most common grade
3 toxicity. Grade 3 non-hematological toxicity included
diarrhea in 22.5%, radiation dermatitis in 9.9% and cystitis
in 4.2% of patients. Grade 3 hand-foot skin reactions were
rarely observed. Hematological toxicity of grade 3 included
leukopenia in 5.6% or patients. No patients had grade 3
thrombocytopenia.
Thirty-seven patients (52.1%) received all planned iri-
notecan doses (mean relative dose intensity of 75.2%),
and 41 patients (57.7%) received all planned capecitabine
doses (mean relative dose intensity 82.4%). Sixty-five pa-
tients (91.5%) received assigned doses of RT as scheduled.
Survival
The median follow-up for living patients after completion
of chemoradiation was 31 months (range, 6–54 months).
At the time of the last follow-up, clinical local control had
been achieved in 42 patients (59.2%), and 43 patientsTable 2 Summary of clinical findings
Parameter No. of patients %
Response* (n = 71)
Pathologic complete response 7 9.9
Clinical complete response 4 5.6
Partial response 22 31.0
Stable disease 33 46.5
Progressive disease 5 7.0
Symptom relief (n = 53)
Complete relief 30 56.6
Partial relief 17 32.1
No relief 6 11.3
*: 14 patients underwent radical resections (R0) post-chemoradiation.developed distant metastases (60.6%). The cumulative
local progression-free survival rate was 74.2% (SE, ±5.2%)
at 1 year after chemoradiation and 33.9% (SE, ±6.4%) at
3 years after chemoradiation. The median local control
time was 25 months. Forty-one patients (57.5%) died, and
the cumulative total survival rate was 80.1% (SE, ±4.8%) at
1 year after chemoradiation and 36.5% (SE, ±6.5%) at
3 years after chemoradiation. The median survival time
after chemoradiation was 29 months. Of the 14 patients
with R0 resections, the cumulative local progression-free
survival rate was 92.3% (SE, ±7.4%) at 1 year after che-
moradiation and 53.3% (SE, ±15.7%) at 3 years after che-
moradiation. Only 5 patients died (35.7%), and the
cumulative total survival rate was 100.0% (SE, ±0%) at
1 year after chemoradiation and 59.4% (SE, ±16.0%) at
3 years after chemoradiation.
Discussion
The medical literature offers little data on the optimum
choice of chemotherapeutic agents to administer con-
currently with radiation when treating recurrent rectal
cancer. The optimal treatment for recurrent rectal can-
cer has not yet been defined. Patients undergoing R0 re-
section have the greatest survival advantage following
surgery for recurrent rectal cancer [18], but many pa-
tients may not be good candidates for further surgery. In
addition, approximately 50% of patients with local recur-
rence have concomitant metastatic disease at the time of
diagnosis [19]. Multimodal treatment may offer superior
outcomes in the treatment of patients with recurrent rec-
tal cancers [9]. In addition, no prospective trial has evalu-
ated the efficacy and safety of irinotecan and capecitabine
concurrent with IMRT for the treatment of recurrent rec-
tal cancer. This study assesses whether IMRT concurrent
with irinotecan and capecitabine is effective and safe in
patients with recurrent rectal cancer without prior pelvic
irradiation. An overall local response rate of 46.5% and
a clinical symptom relief rate of 88.7% were achieved.
Only 2.8% of patients experienced grade 4 leukopenia.
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cystitis were observed in 22.5%, 9.9%, 5.6% and 4.2% of
patients, respectively.
Some dosimetric and clinical studies have shown that
IMRT for rectal cancer can reduce the incidence of
irradiated small bowel and treatment-related toxicities
compared with standard 3-dimensional conformal RT
(3DCRT) [20,21]. Therefore, a relatively higher radiation
dose (55–61 Gy) using IMRT was administered to re-
current sites in our study. A number of phase I and II
trials have evaluated CPT-11, capecitabine combined
with radiation, and demonstrated that this treatment is
well-tolerated and effective for primary rectal cancer.
From these trials, the recommended irinotecan dose
was 40–60 mg/m2/week, and the capecitabine dose was
500–825 mg/m2, twice daily [11-15]. In our study, con-
current chemotherapy consisted of weekly irinotecan at
50 mg/m2 for five consecutive weeks (days 1, 8, 15, 22,
and 29), and 625 mg/m2 capecitabine was administered
orally (weekdays only). The regimen of IMRT concur-
rent with irinotecan and capecitabine is effective and
safe in patients with recurrent rectal cancer.
Our results demonstrated that an overall local control
rate of 93% with a local response rate of 46.5% (complete
response 15.5%) at 3 months after concurrent chemora-
diation and a clinical symptom relief rate of 88.7% were
achieved. These findings compare favorably with previ-
ous trials. Hu et al. [22] investigated the use of 3DCRT
combined with FOLFOX4 chemotherapy in 48 patients
with unresectable recurrent rectal cancer. They reported
a 47.9% overall response rate in all patients. Only 1 pa-
tient achieved a complete response. Another phase II
trial [23] evaluated concurrent oxaliplatin and 5-FU with
RT in 102 patients with isolated locally recurrent rectal
cancer revealing similar results. Complete clinical re-
sponses were observed in 13 of the 96 patients (14%).
These two trials investigated the addition of oxaliplatin
to chemoradiation for the management of locally recur-
rent rectal cancer. Because most recurrent patients have
previously received oxaliplatin after standard adjuvant
chemotherapy (FOLFOX), irinotecan as a radiosensitizer
in the management of recurrent rectal cancer may be a
better treatment choice.
Many phase I and II trials investigating the addition of
irinotecan to neoadjuvant chemoradiation for the treatment
of locally advanced rectal cancer have been reported, and
the pCR rate was ranged from 14% to 26% [12,13,24-26].
In our study, a pathologic complete response was ob-
served in 9.9% (7/71) patients. Our enrolled patients were
diagnosed with recurrent rectal cancer along with 32.4%
(23/71) patients with distant metastases. The proportion
of patients obtaining a clinical symptom relief rate (88.7%)
was similar to that reported for some other concurrent
chemoradiation protocols (>75%) [27].Radical resection of recurrent tumors is crucial for long-
term cure [5,28,29]. However, only 20% to 30% of all
patients with locally recurrent rectal cancer will have a po-
tentially curative operation. In our study, 19.7% (14/71) of
all patients and 29.2% (14/48) of the patients without dis-
tant metastases underwent R0 resections. Of the 14 pa-
tients with R0 resections, only 5 patients died (35.7%), and
the cumulative total survival rate was 100.0% (SE, ±0%) at
1 year after chemoradiation and 59.4% (SE, ±16.0%) at
3 years after chemoradiation.
Interestingly, 4 patients with a complete clinical re-
sponse who did not receive surgery showed good clinical
outcomes. Only 1 patient died as a result of distant
metastasis, and 3 remained disease free at the time of
the analysis. This strategy of close observation for clin-
ical complete responders after preoperative CRT in lo-
cally advanced rectal cancer has been discussed [30] but
requires further study.
The incidence of acute toxicity with IMRT concurrent
with irinotecan and capecitabine for the treatment of recur-
rent rectal cancer was acceptable and manageable. Diarrhea
was the most common acute toxicity. The rate of grade 3
diarrhea (22.5%) in our study was comparable with that re-
ported for irinotecan regimens (11-28%) [12,24,31,32]. Leu-
kocytopenia was the most common hematologic toxicity,
with grade 3–4 recorded in 8.5% of patients. This result is
similar to that reported previously [10].
The major limitation of the current study was the rela-
tively short median follow-up of 31 months. Addition-
ally, data regarding late toxicity are limited. Moreover,
some patients who may have developed late toxicity died
prematurely. The long-term efficacy and toxicity may be
elucidated upon further follow-up.
In conclusion, concurrent irinotecan and capecitabine
with IMRT can significantly relieve local symptoms and
exhibits promising efficacy in recurrent rectal cancer
without prior pelvic irradiation. Toxicity profiles were
acceptable with the dosage and schedule. Improvements
in the rate of R0 resections will be investigated in future
studies. Neoadjuvant chemoradiation combining newer
cytotoxic agents appears promising for the treatment of
recurrent rectal cancer.
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